|
1
|
Gong Z, Wang J, Wang D, Buas MF, Ren X,
Freudenheim JL, Belinsky SA, Liu S, Ambrosone CB and Higgins MJ:
Differences in microRNA expression in breast cancer between women
of African and European ancestry. Carcinogenesis. 40:61–69. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tomao F, Papa A, Zaccarelli E, Rossi L,
Caruso D, Minozzi M, Vici P, Frati L and Tomao S: Triple-negative
breast cancer: New perspectives for targeted therapies. Onco
Targets Ther. 8:177–193. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cardoso F, Costa A, Norton L, Senkus E,
Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL,
et al: ESO-ESMO 2nd international consensus guidelines for advanced
breast cancer (ABC2). Breast. 23:489–502. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Senkus E, Kyriakides S, Ohno S,
Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S and Cardoso
F; ESMO Guidelines Committee, : Primary breast cancer: ESMO
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 26 (Suppl 5):v8–v30. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Li J, Wang F, Sun D and Wang R: A review
of the ligands and related targeting strategies for active
targeting of paclitaxel to tumours. J Drug Target. 24:590–602.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Paridaens R, Biganzoli L, Bruning P, Klijn
JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A,
Sylvester R, et al: Paclitaxel versus doxorubicin as first-line
single-agent chemotherapy for metastatic breast cancer: A European
organization for research and treatment of cancer randomized study
with cross-over. J Clin Oncol. 18:724–733. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gascoigne KE and Taylor SS: How do
anti-mitotic drugs kill cancer cells? J Cell Sci. 122:2579–2585.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kavallaris M: Microtubules and resistance
to tubulin-binding agents. Nat Rev Cancer. 10:194–204. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Koudelka S and Turánek J: Liposomal
paclitaxel formulations. J Control Release. 163:322–334. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yuan P, Shentu J, Xu J, Burke W, Hsu K,
Learoyd M, Zhu M and Xu B: Pharmacokinetics and safety of olaparib
tablets as monotherapy and in combination with paclitaxel: Results
of a Phase I study in Chinese patients with advanced solid tumours.
Cancer Chemother Pharmacol. 83:963–974. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Azimi I, Petersen RM, Thompson EW,
Roberts-Thomson SJ and Monteith GR: Hypoxia-induced reactive oxygen
species mediate N-cadherin and SERPINE1 expression, EGFR signalling
and motility in MDA-MB-468 breast cancer cells. Sci Rep.
7:151402017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Freeberg MAT, Farhat YM, Easa A,
Kallenbach JG, Malcolm DW, Buckley MR, Benoit DSW and Awad HA:
Serpine1 knockdown enhances MMP activity after flexor tendon injury
in mice: Implications for adhesions therapy. Sci Rep. 8:58102018.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang K, Zhang S, Zhang D, Tao Q, Zhang T,
Liu G, Liu X and Zhao T: Identification of SERPINE1, PLAU and ACTA1
as biomarkers of head and neck squamous cell carcinoma based on
integrated bioinformatics analysis. Int J Clin Oncol. 24:1030–1041.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Barrett T, Wilhite SE, Ledoux P,
Evangelista C, Kim IF, Tomashevsky M, Marshall KA, Phillippy KH,
Sherman PM, Holko M, et al: NCBI GEO: Archive for functional
genomics data sets-update. Nucleic Acids Res. 41((Database Issue)):
D991–D995. 2013.PubMed/NCBI
|
|
15
|
The Gene Ontology Consortium, . The gene
ontology resource: 20 Years and still GOing strong. Nucleic Acids
Res. 47(D1): D330–D338. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kanehisa M, Furumichi M, Tanabe M, Sato Y
and Morishima K: KEGG: New perspectives on genomes, pathways,
diseases and drugs. Nucleic Acids Res. 45(D1): D353–D361. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lei Y, Yu D, Bin Z and Yang Y: Interactive
K-means clustering method based on user behavior for different
analysis target in medicine. Comput Math Methods Med.
2017:49158282017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang TN, Li TJ, Shao GF and Wu SX: An
improved K-means clustering method for cDNA microarray image
segmentation. Genet Mol Res. 14:7771–7781. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen S, Dong Q, Hu S, Cai J, Zhang W, Sun
J, Wang T, Xie J, He H, Xing J, et al: Proteomic analysis of the
proteins that are associated with the resistance to paclitaxel in
human breast cancer cells. Mol Biosyst. 10:294–303. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Panayotopoulou EG, Müller AK, Börries M,
Busch H, Hu G and Lev S: Targeting of apoptotic pathways by SMAC or
BH3 mimetics distinctly sensitizes paclitaxel-resistant triple
negative breast cancer cells. Oncotarget. 8:45088–45104. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Edilova MI, Abdul-Sater AA and Watts TH:
TRAF1 signaling in human health and disease. Front Immunol.
9:29692018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu S, Jin J, Gokhale S, Lu AM, Shan H,
Feng J and Xie P: Genetic alterations of TRAF proteins in human
cancers. Front Immunol. 9:21112018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dewangan J, Srivastava S, Mishra S,
Divakar A, Kumar S and Rath SK: Salinomycin inhibits breast cancer
progression via targeting HIF-1α/VEGF mediated tumor angiogenesis
in vitro and in vivo. Biochem Pharmacol. 164:326–335. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Claesson-Welsh L and Welsh M: VEGFA and
tumour angiogenesis. J Intern Med. 273:114–127. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jia J, Zhang H, Zhang H, Du H, Liu W and
Shu M: Activated androgen receptor accelerates angiogenesis in
cutaneous neurofibroma by regulating VEGFA transcription. Int J
Oncol. 55:157–166. 2019.PubMed/NCBI
|
|
26
|
Alluri P and Newman LA: Basal-like and
triple-negative breast cancers: Searching for positives among many
negatives. Surg Oncol Clin N Am. 23:567–577. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Carotenuto P, Roma C, Rachiglio AM, Botti
G, D'Alessio A and Normanno N: Triple negative breast cancer: From
molecular portrait to therapeutic intervention. Crit Rev Eukaryot
Gene Expr. 20:17–34. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kalimutho M, Parsons K, Mittal D, López
JA, Srihari S and Khanna KK: Targeted therapies for triple-negative
breast cancer: Combating a stubborn disease. Trends Pharmacol Sci.
36:822–846. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Burstein MD, Tsimelzon A, Poage GM,
Covington KR, Contreras A, Fuqua SA, Savage MI, Osborne CK,
Hilsenbeck SG, Chang JC, et al: Comprehensive genomic analysis
identifies novel subtypes and targets of triple-negative breast
cancer. Clin Cancer Res. 21:1688–1698. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jhan JR and Andrechek ER: Triple-negative
breast cancer and the potential for targeted therapy.
Pharmacogenomics. 18:1595–1609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lehmann BD, Bauer JA, Chen X, Sanders ME,
Chakravarthy AB, Shyr Y and Pietenpol JA: Identification of human
triple-negative breast cancer subtypes and preclinical models for
selection of targeted therapies. J Clin Invest. 121:2750–2767.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ng CK, Schultheis AM, Bidard FC, Weigelt B
and Reis-Filho JS: Breast cancer genomics from microarrays to
massively parallel sequencing: Paradigms and new insights. J Natl
Cancer Inst. 107:djv0152015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Podo F, Buydens LM, Degani H, Hilhorst R,
Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J,
Monleon D, et al: Triple-negative breast cancer: Present challenges
and new perspectives. Mol Oncol. 4:209–229. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Shah SP, Roth A, Goya R, Oloumi A, Ha G,
Zhao Y, Turashvili G, Ding J, Tse K, Haffari G, et al: The clonal
and mutational evolution spectrum of primary triple-negative breast
cancers. Nature. 486:395–399. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Gardner ER, Dahut WL, Scripture CD, Jones
J, Aragon-Ching JB, Desai N, Hawkins MJ, Sparreboom A and Figg WD:
Randomized crossover pharmacokinetic study of solvent-based
paclitaxel and nab-paclitaxel. Clin Cancer Res. 14:4200–4205. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Schiff PB and Horwitz SB: Taxol stabilizes
microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA.
77:1561–1565. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
ten Tije AJ, Verweij J, Loos WJ and
Sparreboom A: Pharmacological effects of formulation vehicles:
Implications for cancer chemotherapy. Clin Pharmacokinet.
42:665–685. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Menderes G, Lopez S, Han C, Altwerger G,
Gysler S, Varughese J, Schwartz PE and Santin AD: Mechanisms of
resistance to HER2-targeted therapies in HER2-amplified uterine
serous carcinoma, and strategies to overcome it. Discov Med.
26:39–50. 2018.PubMed/NCBI
|
|
40
|
Leik CE, Su EJ, Nambi P, Crandall DL and
Lawrence DA: Effect of pharmacologic plasminogen activator
inhibitor-1 inhibition on cell motility and tumor angiogenesis. J
Thromb Haemost. 4:2710–2715. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Erickson LA, Ginsberg MH and Loskutoff DJ:
Detection and partial characterization of an inhibitor of
plasminogen activator in human platelets. J Clin Invest.
74:1465–1472. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ghosh AK, Murphy SB, Kishore R and Vaughan
DE: Global gene expression profiling in PAI-1 knockout murine heart
and kidney: Molecular basis of cardiac-selective fibrosis. PLoS
One. 8:e638252013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Higgins PJ: Balancing AhR-dependent
pro-oxidant and Nrf2-responsive anti-oxidant pathways in
age-related retinopathy: Is SERPINE1 expression a therapeutic
target in disease onset and progression? J Mol Genet Med.
8:1012014.PubMed/NCBI
|
|
44
|
Freytag J, Wilkins-Port CE, Higgins CE,
Higgins SP, Samarakoon R and Higgins PJ: PAI-1 mediates the
TGF-beta1+EGF-induced ‘scatter’ response in transformed human
keratinocytes. J Invest Dermatol. 130:2179–2190. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Pavón MA, Arroyo-Solera I, Téllez-Gabriel
M, León X, Virós D, López M, Gallardo A, Céspedes MV, Casanova I,
López-Pousa A, et al: Enhanced cell migration and apoptosis
resistance may underlie the association between high SERPINE1
expression and poor outcome in head and neck carcinoma patients.
Oncotarget. 6:29016–29033. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pavón MA, Arroyo-Solera I, Céspedes MV,
Casanova I, León X and Mangues R: uPA/uPAR and SERPINE1 in head and
neck cancer: Role in tumor resistance, metastasis, prognosis and
therapy. Oncotarget. 7:57351–57366. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wu DM, Wang S, Wen X, Han XR, Wang YJ, Fan
SH, Zhang ZF, Shan Q, Lu J and Zheng YL: MircoRNA-1275 promotes
proliferation, invasion and migration of glioma cells via SERPINE1.
J Cell Mol Med. 22:4963–4974. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Yao H, He G, Chen C, Yan S, Lu L, Song L,
Vijayan KV, Li Q, Xiong L, Miao X and Deng X: PAI1: A novel
PP1-interacting protein that mediates human plasma's anti-apoptotic
effect in endothelial cells. J Cell Mol Med. 21:2068–2076. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
McCann JV, Xiao L, Kim DJ, Khan OF,
Kowalski PS, Anderson DG, Pecot CV, Azam SH, Parker JS, Tsai YS, et
al: Endothelial miR-30c suppresses tumor growth via inhibition of
TGF-β-induced Serpine1. J Clin Invest. 130:1654–1670. 2019.
View Article : Google Scholar
|
|
50
|
Takayama Y, Hattori N, Hamada H, Masuda T,
Omori K, Akita S, Iwamoto H, Fujitaka K and Kohno N: Inhibition of
PAI-1 limits tumor angiogenesis regardless of angiogenic stimuli in
malignant pleural mesothelioma. Cancer Res. 76:3285–3294. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Viallard C and Larrivée B: Tumor
angiogenesis and vascular normalization: Alternative therapeutic
targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Luan X, Guan YY, Lovell JF, Zhao M, Lu Q,
Liu YR, Liu HJ, Gao YG, Dong X, Yang SC, et al: Tumor priming using
metronomic chemotherapy with neovasculature-targeted,
nanoparticulate paclitaxel. Biomaterials. 95:60–73. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Samuel S, Fan F, Dang LH, Xia L, Gaur P
and Ellis LM: Intracrine vascular endothelial growth factor
signaling in survival and chemoresistance of human colorectal
cancer cells. Oncogene. 30:1205–1212. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Iqbal S and Lenz HJ: Integration of novel
agents in the treatment of colorectal cancer. Cancer Chemother
Pharmacol. 54 (Suppl 1):S32–S39. 2004.PubMed/NCBI
|
|
55
|
Fallah A, Sadeghinia A, Kahroba H, Samadi
A, Heidari HR, Bradaran B, Zeinali S and Molavi O: Therapeutic
targeting of angiogenesis molecular pathways in
angiogenesis-dependent diseases. Biomed Pharmacother. 110:775–785.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Tsai JL, Lee YM, Pan CY and Lee AY: The
novel VEGF121- VEGF165 fusion attenuates angiogenesis and drug
resistance via targeting VEGFR2-HIF-1α-VEGF165/Lon signaling
through PI3K-AKT-mTOR pathway. Curr Cancer Drug Targets.
16:275–286. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Tonissi F, Lattanzio L, Merlano MC,
Infante L, Lo Nigro C and Garrone O: The effect of paclitaxel and
nab-paclitaxel in combination with anti-angiogenic therapy in
breast cancer cell lines. Invest New Drugs. 33:801–809. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Carmeliet P and Jain RK: Molecular
mechanisms and clinical applications of angiogenesis. Nature.
473:298–307. 2011. View Article : Google Scholar : PubMed/NCBI
|
